Literature DB >> 20565499

Surgical resection of lung adenocarcinoma without EGFR mutation after neoadjuvant gefitinib treatment.

Hong Shen1, Xian Zhong, Xiao-Qin Ge, Jian-Jin Huang, Ying Yuan.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20565499     DOI: 10.1111/j.1752-699X.2009.00167.x

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


× No keyword cloud information.
  6 in total

1.  Radical surgical resection after neoadjuvant targeted therapy in non-small cell lung cancer: a single-center retrospective study of 6 cases.

Authors:  Zhenyang Zhang; Jiangbo Lin; Shuai Peng; Wenwei Lin; Mingqiang Kang
Journal:  J Thorac Dis       Date:  2019-01       Impact factor: 2.895

Review 2.  Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer.

Authors:  Haoran Zhai; Wenzhao Zhong; Xuening Yang; Yi-Long Wu
Journal:  Transl Lung Cancer Res       Date:  2015-02

3.  Rescue Surgery after Immunotherapy/Tyrosine Kinase Inhibitors for Initially Unresectable Lung Cancer.

Authors:  Domenico Galetta; Filippo De Marinis; Lorenzo Spaggiari
Journal:  Cancers (Basel)       Date:  2022-05-27       Impact factor: 6.575

4.  Surgery for advanced non-small cell lung cancer patient after epidermal growth factor receptor tyrosine kinase inhibitor neoadjuvant therapy.

Authors:  Ye Ning; Minwei Bao; Xiaoxia Yan; Dong Xie; Gening Jiang
Journal:  Ann Transl Med       Date:  2018-10

5.  Use of a tyrosine kinase inhibitor as neoadjuvant therapy for non-small cell lung cancer: A case report.

Authors:  A López-González; E Almagro; C Salas; A Varela; M Provencio
Journal:  Respir Med Case Rep       Date:  2013-04-24

Review 6.  Surgical resection of advanced non-small cell lung cancer after a response to EGFR-TKI: presentation of two cases and a literature review.

Authors:  Yoko Yamamoto; Ken Kodama; Tomohiro Maniwa; Masashi Takeda
Journal:  J Cardiothorac Surg       Date:  2017-11-23       Impact factor: 1.637

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.